Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Concurrent partial splenic embolization with transcatheter arterial chemoembolization for hepatocellular carcinoma can maintain hepatic functional reserve.

Ishikawa T, Kubota T, Horigome R, Kimura N, Honda H, Iwanaga A, Seki K, Honma T, Yoshida T.

Hepatol Res. 2014 Oct;44(11):1056-61. doi: 10.1111/hepr.12222. Epub 2013 Sep 8.

2.

[The significance of combined treatment for hepatocellular carcinoma with partial splenic embolization and transcatheter arterial chemoembolization using IA call/lipiodol].

Harao M, Beppu T, Masuda T, Hayashi H, Okabe H, Okabe K, Imseung C, Komori H, Horino K, Baba H.

Gan To Kagaku Ryoho. 2008 Nov;35(12):2027-9. Japanese.

PMID:
19106512
3.

[Study on primary hepatocellular carcinoma associated with hypersplenism treated by partial splenic embolization combined with hepatic arterial chemoembolization].

Huang JH, Wu PH, Gu YK, Zhang FJ, Li CX, Gao F, Zhang L, Fan WJ, Li CJ.

Ai Zheng. 2006 Aug;25(8):1003-6. Chinese.

PMID:
16965683
4.

[Splenic embolization and hepatic chemoembolization: combined transcatheter treatment of hepatocellular carcinoma in cirrhosis with hypersplenism].

Roversi R, Ricci S, Gambari PI, Castaldini L, Rossi G, Milandri G, Formica G, Dalmonte PR.

Radiol Med. 1993 Apr;85(4):444-9. Italian.

PMID:
8390705
5.
6.

Partial splenic embolization with transarterial chemoembolization in patients with hepatocellular carcinoma accompanied by thrombocytopenia.

Ooka Y, Chiba T, Ogasawara S, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O.

Biomed Res Int. 2014;2014:960628. doi: 10.1155/2014/960628. Epub 2014 Sep 15.

7.

Partial splenic embolization for hypersplenism concomitant with or after arterial embolization of hepatocellular carcinoma in 30 patients.

Han MJ, Zhao HG, Ren K, Zhao DC, Xu K, Zhang XT.

Cardiovasc Intervent Radiol. 1997 Mar-Apr;20(2):125-7.

PMID:
9030503
8.

[Usefulness of partial splenic embolization (PSE) in hepatocellular carcinomas showing a risk of gastrointestinal bleeding after transcatheter arterial embolization (TAE)].

Ohmoto K, Yamamoto R, Yamamoto S, Ideguchi S, Saito I, Wada A, Takatori K, Ohumi T, Hino K, Hirano Y.

Gan No Rinsho. 1989 May;35(6):690-5. Japanese.

PMID:
2542638
9.

Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation.

Hidaka H, Kokubu S, Nakazawa T, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Saigenji K.

Hepatol Res. 2009 Aug;39(8):772-8. doi: 10.1111/j.1872-034X.2009.00508.x. Epub 2009 Mar 25.

PMID:
19473438
10.
12.

Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications.

Cai M, Huang W, Lin C, Li Z, Qian J, Huang M, Zeng Z, Huang J, Shan H, Zhu K.

Eur Radiol. 2016 Feb;26(2):370-80. doi: 10.1007/s00330-015-3839-4. Epub 2015 May 23.

PMID:
26002134
14.

Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients.

N'Kontchou G, Seror O, Bourcier V, Mohand D, Ajavon Y, Castera L, Grando-Lemaire V, Ganne-Carrie N, Sellier N, Trinchet JC, Beaugrand M.

Eur J Gastroenterol Hepatol. 2005 Feb;17(2):179-84.

PMID:
15674095
15.

Usefulness of preoperative partial splenic embolization in hepatocellular carcinoma and hypersplenic thrombocytopenia.

Yoshidome H, Kimura F, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Suda K, Takano S, Miyazaki M.

Hepatogastroenterology. 2011 Nov-Dec;58(112):2062-6. doi: 10.5754/hge09590.

PMID:
22234078
16.

A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma.

Bayraktar Y, Balkanci F, Kayhan B, Uzunalimoglu B, Gokoz A, Ozisik Y, Gurakar A, Van Thiel DH, Firat D.

Hepatogastroenterology. 1996 May-Jun;43(9):681-7.

PMID:
8799415
17.

Efficacy and safety of transcatheter chemoembolization of the internal thoracic artery in patients with hepatocellular carcinoma.

Fan QS, Huo XK, Wang MQ, Liu FY, Duan F, Wang ZJ, Song P.

Chin Med J (Engl). 2011 May;124(9):1374-80.

PMID:
21740751
18.

Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis.

Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB.

Aliment Pharmacol Ther. 2009 Jun 15;29(12):1291-8. doi: 10.1111/j.1365-2036.2009.04016.x. Epub 2009 Apr 8.

19.

Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.

Biselli M, Andreone P, Gramenzi A, Trevisani F, Cursaro C, Rossi C, Ricca Rosellini S, Cammà C, Lorenzini S, Stefanini GF, Gasbarrini G, Bernardi M.

Clin Gastroenterol Hepatol. 2005 Sep;3(9):918-25.

PMID:
16234031
20.

Supplemental Content

Support Center